Pharmaceutical

Lilly looks to double pipeline size again

February 23, 2011
J.K. Wall
Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.
More

Lilly's master plan for downtown (real estate)

February 19, 2011
Cory Schouten
As Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian streets 135 years ago.
More

Emerging markets give Lilly hope in patent crunch

February 19, 2011
J.K. Wall
In a kind of alternate drug universe, sales of Eli Lilly and Co.’s ghosts of blockbusters past are soaring in China—prompting the drugmaker to pour money into emerging markets in an attempt to prop up revenue.
More

Lilly takeover provision to be voted on again

February 11, 2011
Scott Olson
The effort to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly's board is on the agenda of the company's April 18 annual meeting.
More

Lilly names new head of cancer drug business

February 11, 2011
Associated Press
Eli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
More

Arcadia reports smaller loss on increased revenue

February 9, 2011
The Indianapolis-based health care company lost $2.3 million on revenue of $26.2 million in its third fiscal quarter.
More

Recent successes don't change Lilly's outlook

February 9, 2011
J.K. Wall
Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.
More

Lilly collaboration with outside researchers yields first deal

February 8, 2011
Chris O'Malley
Eli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz said it's just the first of many such collaborations.
More

Endocyte again changes terms of public offering

February 4, 2011
 IBJ Staff and Bloomberg News
The West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more than previously announced, but at a lower price of $6 each.
More

Lilly, Bristol-Myers halt enrollment in lung-cancer trial

February 2, 2011
J.K. Wall
Eli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung cancer drug over concerns about patients developing blood clots.
More

Potential competitor to Lilly drug shows promise in study

February 2, 2011
 IBJ Staff and Bloomberg News
Sanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
More

Marcadia may fetch up to $537 million in sale

February 2, 2011
J.K. Wall
The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes medicines.
More

Mini Thin marketer slapped with suitRestricted Content

January 29, 2011
Kathleen McLaughlin
A Carmel man whose Mini Thin dietary supplement was sold through convenience stores nationwide before the government banned its active ingredient now faces allegations of bankruptcy fraud.
More

Lilly product gets boost; Wall Street yawns

January 26, 2011
J.K. Wall
Eli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease, but so far analysts are unimpressed.
More

Head of Lilly's oncology unit resigning

January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
More

Vanderbilt rejected by high court on Cialis patents

January 24, 2011
Bloomberg News
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly's Icos subsidiary.
More

21st Century Fund pockets a payoff from saleRestricted Content

January 22, 2011
Chris O'Malley
The state’s principal fund investing in high-tech companies has reached a milestone—for the first time recouping all the money it granted an emerging company, and then some.
More

Lilly seeks to block imports of cancer drug copy

January 21, 2011
Bloomberg News
The local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent on the process for making the active ingredient.
More

Lilly imaging drug fails to win FDA panel's backing

January 21, 2011
Bloomberg News
Eli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
More

Down on luck, Lilly finds comfort in pets

January 19, 2011
J.K. Wall
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
More

Carmel firm gets FDA approval for lice treatment

January 18, 2011
 IBJ Staff
ParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
More

Lilly imaging drug isn't ready for approval, FDA says

January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval, according to U.S. regulators.
More

Endocyte prices IPO stock

January 14, 2011
J.K. Wall
The West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch $80 million to $92 million.
More

Panel says Lilly’s Solpura isn’t ready for approval

January 12, 2011
Bloomberg News
Eli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that isn’t derived from pig parts.
More

Deal could give Lilly full diabetes deck

January 12, 2011
J.K. Wall
Eli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy that some consultants think is key to pharma companies’ futures.
More
Page  << 11 12 13 14 15 16 17 18 19 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT